Devyser Diagnostics AB (publ) (DVYSR.ST)

SEK 117.0

(0.0%)

Operating Expenses Summary of Devyser Diagnostics AB (publ)

  • Devyser Diagnostics AB (publ)'s latest annual operating expenses in 2023 was 204.6 Million SEK , up 27.3% from previous year.
  • Devyser Diagnostics AB (publ)'s latest quarterly operating expenses in 2024 Q1 was 57.9 Million SEK , up 3.21% from previous quarter.
  • Devyser Diagnostics AB (publ) reported a annual operating expenses of 160.71 Million SEK in annual operating expenses 2022, up 66.6% from previous year.
  • Devyser Diagnostics AB (publ) reported a annual operating expenses of 96.47 Million SEK in annual operating expenses 2021, up 51.67% from previous year.
  • Devyser Diagnostics AB (publ) reported a quarterly operating expenses of 55.9 Million SEK for 2024 Q3, down -8.96% from previous quarter.
  • Devyser Diagnostics AB (publ) reported a quarterly operating expenses of 57.9 Million SEK for 2024 Q1, up 3.21% from previous quarter.

Annual Operating Expenses Chart of Devyser Diagnostics AB (publ) (2023 - 2018)

Historical Annual Operating Expenses of Devyser Diagnostics AB (publ) (2023 - 2018)

Year Operating Expenses Operating Expenses Growth
2023 204.6 Million SEK 27.3%
2022 160.71 Million SEK 66.6%
2021 96.47 Million SEK 51.67%
2020 63.6 Million SEK 45.79%
2019 43.62 Million SEK 13.88%
2018 38.31 Million SEK 0.0%

Peer Operating Expenses Comparison of Devyser Diagnostics AB (publ)

Name Operating Expenses Operating Expenses Difference
AroCell AB (publ) 57.68 Million SEK -254.703%
Immunovia AB (publ) 291.35 Million SEK 29.776%
Prostatype Genomics AB (publ) 3.22 Million SEK -6244.186%
SenzaGen AB 49.67 Million SEK -311.902%
Spermosens AB 10.72 Million SEK -1807.692%